# Caplin Point Laboratories (CAPLIPOINT) — Stock analysis > Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/caplipoint ## Current market snapshot - Exchange: NSE - Country: India - Price: ₹2,381.7 - Change: -1.64% - As of: 2026-11-06 - 1D return: -1.64% - 5D return: +2.41% - 1M return: -6.56% - Latest complete quarter: — ## Faxioms Analysis _As of 2026-11-06_ ### Technical Outlook As of 2026-11-06, CAPLIPOINT trades at ₹2381.70, reflecting a mixed technical posture across timeframes. The daily trend is bearish, with price trading below the 20-period and 50-period EMAs and the Supertrend indicator signaling downside pressure. Despite this short-term weakness, the stock remains above its 20-period SMA and 200-period SMA, suggesting longer-term support holds. Conversely, the monthly chart shows a bullish structure, with price above all supplied moving averages and the Supertrend, indicating a broader upward bias that contrasts with recent daily declines. Momentum is developing but not yet decisive; the daily ADX stands at 22.22, while the weekly ADX is slightly stronger at 24.26. Volatility is elevated, with annualized volatility at +38.4% and an ATR of 3.37%. The stock is currently positioned in the middle of its 20-day (+51.3%) and 252-day (+59.2%) ranges, having pulled back from recent highs. Key resistance lies near ₹2388–₹2405, while immediate support is found at ₹2366. An active monthly Inside Bar pattern suggests consolidation, awaiting direction. - Trend Divergence: Daily indicators (Supertrend, EMAs) are bearish, while monthly indicators remain bullish, creating a conflicting signal between short-term momentum and long-term structure. - Key Levels: Immediate resistance is clustered at ₹2388–₹2405 (0.27%–0.97% above current price); support sits at ₹2366 (0.66% below). - Volatility & Range: Annualized volatility is high at +38.4%; price is mid-range within both 20-day (+51.3%) and yearly (+59.2%) bands, indicating no extreme overbought or oversold conditions. - Pattern Watch: An active monthly Inside Bar formation suggests potential for a breakout or breakdown; confirmation requires a move beyond the range boundaries. - Inside Bar - Morning Star - Bullish Engulfing Reversal - Bearish Engulfing Reversal - Outside Bar ### News Context Caplin Point Laboratories Limited has scheduled its Board of Directors meeting for November 12, 2026, to approve unaudited financial results for the quarter and half-year ended September 30, 2026. The company will host a virtual conference call with analysts and institutional investors on the same day at 4:30 PM IST to discuss performance. In compliance with SEBI insider trading regulations, the trading window for Designated Persons and their immediate relatives is closed from October 1, 2026, to November 14, 2026. As of November 6, 2026, the stock closed at ₹2,381.70, reflecting a -1.6% daily decline and an -11.1% one-month return. Technical indicators show a bearish daily trend with the price trading below key moving averages, while the monthly trend remains bullish. The stock carries an annualized volatility of +38.4% and is currently in a -16.9% drawdown from recent highs. Shareholding data as of September 30, 2026, indicates promoters hold 70.57% of the equity, with the public holding 29.43%. - CORPORATE CALENDAR: Board meeting set for Nov 12, 2026, to approve Q2/H1 FY2027 results; investor call scheduled for 4:30 PM IST on the same day. - TRADING WINDOW: Closed for Designated Persons from Oct 1 to Nov 14, 2026, per SEBI regulations. - PRICE ACTION: Stock closed at ₹2,381.70 on Nov 6, down -1.6% daily and -11.1% over the past month, with a market cap of ~₹18,405 crore. - TECHNICALS: Daily trend is bearish (Supertrend signal negative) with resistance near ₹2,388–₹2,405; monthly trend remains bullish despite short-term weakness. - Financial Results |Meeting Date: 12-Nov-2026 - Board Meeting Intimation |Meeting Date: 12-Nov-2026 - Caplin Point Laboratories Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates - Caplin Point Laboratories Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL - AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 70.57 | PUBLIC_VAL: 29.43 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 21-Oct-2026 | REVISION_DT: - ### Official Filings Caplin Point Laboratories Limited has scheduled its Board Meeting for November 12, 2026, to approve unaudited financial results for Q2 and H1 FY2027. Following the results, an earnings conference call is set for the same day at 4:30 PM IST. Shareholding data as of September 30, 2026, indicates promoters hold 70.57% of equity, with the public holding 29.43%. Governance stability was reinforced at the 35th Annual General Meeting on September 25, 2026, where shareholders approved the re-appointment of Dr. Sridhar Ganesan as Managing Director (98.94%), continuation of Mr. C. C. Paarthipan as Chairman (98.72%), and appointment of Mr. D. Muralidharan as Whole-Time Director (96.78%). A trading window closure for designated persons runs from October 1 to November 16, 2026, in compliance with insider trading regulations. - Board meeting on November 12, 2026, to approve Q2/H1 FY2027 financial results; earnings call scheduled for 4:30 PM IST on the same day. - Promoter holding stands at 70.57% and public holding at 29.43% as of September 30, 2026. - Key leadership roles confirmed via shareholder votes exceeding 96% at the September 25, 2026 AGM. - Trading window closed for designated persons from October 1 to November 16, 2026, pending result declaration. - [Financial Results |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_02112026180008_BM_Intimation_Q2__26-27__Signed.pdf) - [Board Meeting Intimation |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_10106_WebXMLFile_20261102_180144694.xml) - [Caplin Point Laboratories Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_02112026181011_Analyst_Meet_SE_intimation_Q2_sd.pdf) - [Caplin Point Laboratories Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_10106_WebXMLFile_20261102_181335305.xml) - [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 70.57 | PUBLIC_VAL: 29.43 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 21-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742873_21102026033543_WEB.xml) - [Caplin Point Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |SUBJECT: Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_07102026151301_SEintimation_SD.pdf) - [CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_10106_WebXMLFile_20260928_170958163.xml) - [Caplin Point Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026 |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_25092026153554_Caplin_Point_Proceedings_of_35th_AGM_sd.pdf) - [Caplin Point Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 25, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_25092026191305_Scrutinizer_Report_signed_final.pdf) - [MEETING DATE : 25-SEP-2026](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1728604_25092026071554_WEB.xml) ### Fundamentals Caplin Point Laboratories demonstrates robust earnings growth and strong cash generation, though recent balance-sheet metrics signal a shift in working-capital efficiency. For the trailing twelve months (TTM) ending around November 2026, sales reached ₹2,287 crore with an 18% compounded profit growth rate over three years. Net profit for TTM stood at ₹678 crore, up from ₹650 crore in FY2026, while EPS rose to ₹87.53. Operating profit margin remained healthy, with operating profit of ₹797 crore against sales of ₹2,287 crore. Cash flow quality is a standout feature: CFO/EBITDA conversion improved to 87% in FY2026, and Cash from Operating Activities surged to ₹523 crore, significantly outpacing investing outflows of ₹582 crore. The company maintains a debt-free profile, with borrowings stable around ₹221 crore and interest expenses negligible at ₹1 crore TTM. However, working-capital efficiency has deteriorated; the Cash Conversion Cycle widened to 194 days in Mar 2026 from 175 days in Mar 2025, driven by a rise in Debtor Days to 138 days and Inventory Days to 181 days. Return on Capital Employed (ROCE) dipped slightly to 24% in FY2026 from 26% in prior years, reflecting the impact of increased investments (₹859 crore) and fixed assets (₹580 crore). The most critical checkpoint is whether the expansion in receivables and inventory stabilizes as new capacities come online, ensuring that rising sales translate into sustained free cash flow rather than trapped working capital. - Earnings Momentum: TTM net profit grew to ₹678 crore (from ₹650 crore in FY2026), with EPS rising to ₹87.53; 3-year compounded profit growth stands at 19%. - Cash Generation Strength: CFO/EBITDA conversion improved to 87% in FY2026, generating ₹523 crore in operating cash flow despite heavy investing outflows of ₹582 crore. - Working Capital Deterioration: Cash Conversion Cycle widened to 194 days in Mar 2026 (from 175 days in Mar 2025), driven by higher Debtor Days (138 days) and Inventory Days (181 days). - Balance Sheet Health: Company remains effectively debt-free with minimal interest costs (₹1 crore TTM); however, ROCE declined to 24% in FY2026 amid significant asset base expansion. ### Bear Case Technical indicators for Caplin Point Laboratories on November 6, 2026, signal a near-term bearish environment despite longer-term bullish trends. The daily Supertrend is bearish, supported by a negative slope in both the 20-day EMA (-5.07) and SMA (-59.67). On the weekly timeframe, the Supertrend also remains bearish with a steep negative EMA slope (-60.73), suggesting sustained selling pressure over recent weeks. Price action reflects this weakness, with the stock closing at ₹2,381.70, down from the previous close of ₹2,421.40. The stock has experienced a significant current drawdown of -16.9% from its peak, following a maximum historical drawdown of -41.7%. Short-term returns are negative across multiple horizons: -1.6% over one day, -6.6% over 20 days, and -11.1% over one month. While the monthly trend remains bullish (Supertrend direction: bullish), the divergence between short-term technical breakdowns and longer-term momentum highlights elevated volatility, evidenced by an annualized volatility of +38.4% and an ATR of 3.37%. Immediate resistance is tight at ₹2,388.13, while support lies lower at ₹2,366.07. - Daily and weekly Supertrend indicators are both bearish, with negative slopes on key moving averages indicating persistent downward price pressure. - The stock is in a current drawdown of -16.9%, having fallen -11.1% over the past month and -6.6% over the last 20 trading days. - High volatility persists with an annualized volatility of +38.4% and an Average True Range (ATR) of 3.37%, reflecting significant price swings. - Immediate technical resistance is clustered tightly around ₹2,388–₹2,405, while the first support level sits at ₹2,366.07. - [Financial Results |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_02112026180008_BM_Intimation_Q2__26-27__Signed.pdf) - [Board Meeting Intimation |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_10106_WebXMLFile_20261102_180144694.xml) - [Caplin Point Laboratories Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_02112026181011_Analyst_Meet_SE_intimation_Q2_sd.pdf) - [Caplin Point Laboratories Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_10106_WebXMLFile_20261102_181335305.xml) - [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 70.57 | PUBLIC_VAL: 29.43 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 21-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742873_21102026033543_WEB.xml) - [Caplin Point Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |SUBJECT: Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_07102026151301_SEintimation_SD.pdf) - [CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_10106_WebXMLFile_20260928_170958163.xml) - [Caplin Point Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026 |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_25092026153554_Caplin_Point_Proceedings_of_35th_AGM_sd.pdf) - [Caplin Point Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 25, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_25092026191305_Scrutinizer_Report_signed_final.pdf) - [MEETING DATE : 25-SEP-2026](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1728604_25092026071554_WEB.xml) ### FAQs **What are the key upcoming events for Caplin Point Laboratories?** The Board of Directors will meet on November 12, 2026, to approve unaudited financial results for the quarter and half-year ended September 30, 2026. A virtual conference call with analysts and institutional investors is scheduled for the same day at 4:30 PM IST to discuss performance. Additionally, the trading window for Designated Persons remains closed from October 1, 2026, to November 14, 2026. **How has the stock performed over different time horizons as of November 6, 2026?** As of November 6, 2026, the stock has gained +32.4% year-to-date and +29.3% over the last six months. However, it has declined -11.1% over the past month and -7.9% over three months. The one-year return stands at +18.8%, while the current drawdown from recent highs is -16.9%. **What does the shareholding pattern indicate about ownership structure?** As of September 30, 2026, promoters and their group held 70.57% of the equity, while the public holding was 29.43%. Employee holdings were reported at 0%. This concentration indicates that promoter sentiment remains a primary driver of the stock's liquidity and price action. **What are the immediate technical support and resistance levels?** On the daily chart, the stock faces immediate resistance near ₹2,388 (low/high) and ₹2,405. Support is located at ₹2,366. The broader monthly trend remains bullish, but the daily and weekly trends show bearish signals, with the stock closing at ₹2,381.70 on November 6, down from its previous close of ₹2,421.40. - [Financial Results |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_02112026180008_BM_Intimation_Q2__26-27__Signed.pdf) - [Board Meeting Intimation |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_10106_WebXMLFile_20261102_180144694.xml) - [Caplin Point Laboratories Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_02112026181011_Analyst_Meet_SE_intimation_Q2_sd.pdf) - [Caplin Point Laboratories Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_10106_WebXMLFile_20261102_181335305.xml) - [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 70.57 | PUBLIC_VAL: 29.43 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 21-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742873_21102026033543_WEB.xml) - [Caplin Point Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |SUBJECT: Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_07102026151301_SEintimation_SD.pdf) - [CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_10106_WebXMLFile_20260928_170958163.xml) - [Caplin Point Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026 |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_25092026153554_Caplin_Point_Proceedings_of_35th_AGM_sd.pdf) - [Caplin Point Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 25, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_25092026191305_Scrutinizer_Report_signed_final.pdf) - [MEETING DATE : 25-SEP-2026](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1728604_25092026071554_WEB.xml) ## Technical analytics - As of: 2026-11-06 - Daily trend: Weak Uptrend - Weekly trend: Weak Downtrend - Pivot point: ₹2,426.83 - Risk regime: Price Risk Requires Attention ### Support levels - 2022.5 - 1954.9 - 1947.08125 ### Resistance levels - 2388.75 - 2450.5750000000003 - 2601 ### Return and range metrics | Metric | Value | | --- | --- | | return_1 | -1.64% | | return_10 | +7.19% | | return_1m | -11.12% | | return_1y | +18.82% | | return_20 | -6.56% | | return_3m | -7.89% | | return_5 | +2.41% | | return_6m | +29.35% | | return_since_start | -5.20% | | return_ytd | +32.40% | ### Risk and volatility metrics | Metric | Value | | --- | --- | | state | elevated_risk | | label | Price risk requires attention | | summary | Recent drawdown or price variability is high enough to warrant closer monitoring. | | maximum_drawdown | -41.75% | | annualized_volatility | +38.43% | ## Quarterly financials Quarterly financials are not currently available. ## Shareholding pattern - Quarter: FY2027-Q1 - As of: 2026-06-30 - Promoter holding: +70.57% - FII holding: +5.76% - DII holding: +2.49% - Mutual fund holding: +2.03% - Retail holding: +12.14% - Promoter pledged: +0.00% ### Major reported shareholders - P VIJAYALAKSHMI — +24.71% - PAARTHIPAN C C — +18.64% - ASHOK GORKEY PARTHEEBAN — +11.91% - PARTHEEBAN VIVEK SIDDARTH — +11.85% - INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS — +2.87% - MAY INDIA PROPERTY PRIVATE LIMITED — +2.79% (Bodies Corporate) - UTI MULTI CAP FUND — +1.81% - PINEBRIDGE GLOBAL FUNDS - PINEBRIDGE INDIA EQUITY FUND — +1.05% - FIRST DIMENSION HOLDINGS PRIVATE LIMITED — +0.49% (Bodies Corporate) - KIRAVIZ PROPERTIES AND CONSULTANCY LLP — +0.20% (Bodies Corporate) ## Official filings - 2026-11-02 — Board Meeting Notice: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_02112026180008_BM_Intimation_Q2__26-27__Signed.pdf) - 2026-11-02 — Board Meeting Notice: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_10106_WebXMLFile_20261102_180144694.xml) - 2026-11-02 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_02112026181011_Analyst_Meet_SE_intimation_Q2_sd.pdf) - 2026-11-02 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_10106_WebXMLFile_20261102_181335305.xml) - 2026-10-21 — Shareholding Disclosure: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742873_21102026033543_WEB.xml) - 2026-10-07 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_07102026151301_SEintimation_SD.pdf) - 2026-09-28 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_10106_WebXMLFile_20260928_170958163.xml) - 2026-09-25 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_25092026153554_Caplin_Point_Proceedings_of_35th_AGM_sd.pdf) - 2026-09-25 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_25092026191305_Scrutinizer_Report_signed_final.pdf) - 2026-09-25 — Regulatory Filing: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1728604_25092026071554_WEB.xml) - 2026-09-24 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/content/RSS/Online_announcements.xml) - 2026-09-24 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_24092026183956_Spult_in_volume_sd.pdf) - 2026-09-04 — Corporate Action Notice: Caplin Point Laboratories Limited - Ex-Date: 18-Sep-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions) - 2026-09-04 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_04092026150707_Letter_to_Shareholder_sd.pdf) - 2026-09-04 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_04092026152041_AGM_Newspaper_Ad_Intimation_LH_sd.pdf) - 2026-09-03 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_03092026124351_SE_Intimation__NOTICE_signed.pdf) - 2026-09-03 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_03092026124934_BRSR_2025-26_SE_intimation_signed.pdf) - 2026-09-03 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_10106_WebXMLFile_20260903_172151981.xml) - 2026-09-03 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_10106_WebXMLFile_20260903_172143068.xml) - 2026-09-02 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_02092026172729_Spurt_in_Volume_sd.pdf) - 2026-09-02 — Annual Report: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/annual_reports/AR_31201_CAPLIPOINT_2025_2026_A_18753031_03092026123603.pdf) - 2026-09-01 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/content/RSS/Online_announcements.xml) - 2026-09-01 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_01092026175916_INVIMA_Facility_Approval_SD.pdf) - 2026-08-21 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_21082026191221_Stock_Exchange_intimation_of_USFDA_Audit_signed.pdf) - 2026-08-19 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_19082026180100_SE_Transcript_final.pdf) ## News and market events - 2026-09-25 — Mint: **Indian stock market slides, but 28 Nifty 500 stocks hit fresh 1-year highs this week; MCX, PVR Inox among them** — The Nifty 50 index experienced its biggest decline since 2020, down 0.88% over the last week. Despite a wider market sell-off, stocks like Welspun Corp and Zydus Lifesciences reached new peaks, highlighting selective investor interest amid high crude oil prices and global bond yield fluctuations. — [Source](https://www.livemint.com/market/stock-market-news/indian-stock-market-slides-but-28-nifty-500-stocks-hit-fresh-1-year-highs-this-week-mcx-pvr-inox-among-them-11790344289040.html) - 2026-09-25 — Times of India: **Top stocks to buy today: Stock market recommendations for September 25, 2026 - check list** — Stock market recommendations: Godrej Agrovet, Caplin Point Laboratories, and Tilaknagar Industries are the top stock picks that Hitesh Rathi, Technical — [Source](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-september-25-2026-godrej-agrovet-caplin-point-laboratories-tilaknagar-industries-stocks-to-buy-today/articleshow/134473586.cms) - 2026-09-25 — Mint: **Raja Venkatraman recommends two stocks for 25 September** — Market expert Raja Venkatraman shares his top stock picks for 25 September. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-two-stocks-for-25-september-11790297595041.html) - 2026-09-25 — Mint: **Stock recommendations for 25 September from MarketSmith India** — MarketSmith India reveals its top stock recommendations for today, 25 September. Get expert insights into the best-performing stocks to guide your investment decisions. — [Source](https://www.livemint.com/market/stock-market-news/stock-recommendations-for-25-september-from-marketsmith-india-11790252543786.html) - 2026-09-09 — MONEYCONTROL: **Trade Spotlight: How should you trade Marico, Narayana Hrudayalaya, Granules, Laurus Labs, Caplin Point, Tata Technologies, and others on September 9?** — Trade Spotlight — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-marico-narayana-hrudayalaya-granules-laurus-labs-caplin-point-tata-technologies-and-others-on-september-9-14025670.html) - 2026-09-04 — Mint: **Stock market today: Gift Nifty hints a positive start; eight day trading stocks to buy on Friday, 4 September** — Indian stock market indices, Sensex and Nifty 50, are expected to open higher on 4 September, following positive global cues. Previous sessions saw declines, but easing bond yields may boost risk assets. Cautious trading is projected ahead of key US nonfarm payrolls data. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-gift-nifty-hints-a-positive-start-eight-day-trading-stocks-to-buy-on-friday-4-september-11788485416492.html) - 2026-09-02 — BUSINESSTODAY: **Mphasis, Engineers India, Caplin Point: Top stocks to trade — Key levels, target prices & stop loss** — Stocks to buy, Stock picks, Stocks to trade, trading views, Mphasis, Caplin Point Laboratories, Engineers India, Mphasis shares, Caplin Point shares, Engineers India shares, Mphasis share price, Caplin Point share price, Engineers India share price, Mphasis stock price, Caplin Point stock price, Engineers India stock price, Mphasis target price, Caplin Point target price, Engineers India target price — [Source](https://www.businesstoday.in/markets/stocks/story/mphasis-engineers-india-caplin-point-top-stocks-to-trade-key-levels-target-prices-stop-loss-552713-2026-09-02) - 2026-09-02 — CNBC-TV18: **These are the three Pharma stocks that should be on your radar today** — All the three Pharma stocks in focus today, Gland Pharma, Caplin Point and Nephrocare Health, have risen between 50% to 70% so far this year. — [Source](https://www.cnbctv18.com/market/pharma-stocks-today-caplin-point-gland-pharma-nephrocare-health-services-share-price-usfda-gmp-acquisition-impact-19981919.htm) - 2026-08-24 — MONEYCONTROL: **Heranba Industries gains 3% as Q1 profit rises; Aurobindo Pharma, Caplin Point Labs fall on USFDA observations** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/heranba-industries-gains-3-as-q1-profit-rises-aurobindo-pharma-caplin-point-labs-fall-on-usfda-observations-14013467.html) - 2026-08-24 — BUSINESS: **Stock Alert: Caplin Point Lab, Natco pharma, Federal Bank, B. R. Goyal Infra** — Shares of Steel Authority of India (SAIL) barred from fresh F&O positions on 24 August 2026. — [Source](https://www.business-standard.com/markets/capital-market-news/stock-alert-caplin-point-lab-natco-pharma-federal-bank-b-r-goyal-infra-126082400105_1.html) - 2026-08-24 — Economic Times: **Stocks in news: Reliance Industries, Bank of Baroda, Power Grid, NATCO Pharma and JSW Infra** — Indian equity markets closed largely unchanged on Friday, August 21, after a volatile trading session. Several companies, including Reliance Industries and Bank of Baroda, reported significant corporate developments. Power Grid Corporation and Jubilant Pharmova also announced key project wins and regulatory approvals. NATCO Pharma and Caplin Point Laboratories received observations from the US FDA after inspections. Mobile manufacturing stocks are expected to gain attention following a new gover... — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-reliance-industries-bank-of-baroda-power-grid-natco-pharma-and-jsw-infra/articleshow/133444199.cms) - 2026-08-23 — CNBC-TV18: **Stocks to Watch for August 24: Reliance Industries, NATCO Pharma, Bank of Baroda** — RIL shareholders approved resolutions on Aug 20, 2026. Caplin Point, NATCO Pharma, and Choksi Labs received US FDA Form 483 observations. Mobile & EMS stocks in focus after new manufacturing scheme. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-24-reliance-industries-natco-pharma-bank-of-baroda-federal-bank-jubilant-pharmova-apollo-micro-systems-19974715.htm) - 2026-08-22 — BUSINESS: **Caplin Point Laboratories' arm receives Form 483 with 10 observations from USFDA** — Caplin Point Laboratories announced that the US Food and Drug Administration (USFDA) conducted an unannounced inspection of its subsidiary Caplin Steriles' injectable and ophthalmic manufacturing facility in Gummidipoondi, Tamil Nadu. — [Source](https://www.business-standard.com/markets/capital-market-news/caplin-point-laboratories-arm-receives-form-483-with-10-observations-from-usfda-126082200115_1.html) - 2026-08-21 — CNBC-TV18: **Caplin Point arm gets 10 USFDA observations after unannounced inspection; no data integrity issues** — The USFDA issued 10 observations after inspecting Caplin Steriles’ Gummidipoondi facility. The company said they are procedural in nature, with none related to data integrity or repeated from earlier inspections. — [Source](https://www.cnbctv18.com/business/companies/caplin-point-arm-gets-10-usfda-observations-after-unannounced-inspection-no-data-integrity-issues-19974709.htm) - 2026-07-15 — The Hindu: **Gift Nifty points to flat opening; earnings, global cues to drive markets today** — Investor focus has shifted to the earnings season, with global cues and easing oil prices expected to drive market sentiment — [Source](https://www.thehindubusinessline.com/markets/gift-nifty-points-to-flat-opening-earnings-global-cues-to-drive-markets-today/article71223872.ece) - 2026-07-15 — The Hindu: **Sensex today | Stock Market Live: Stock to buy today: Caplin Point Laboratories** — Sensex, Nifty, Share Prices LIVE: The short-term outlook is bullish for Caplin Point Laboratories. The stock has been consolidating within its broader uptrend for more than two weeks between ₹2,500 and ₹2,700. We expect the stock to make a bullish breakout above ₹2,700 and resume the broader uptrend. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-15-july-2026/article71220956.ece) - 2026-07-15 — The Hindu: **Stock to buy today: Caplin Point Laboratories (₹2,658) – BUY** — Traders can buy Caplin Point Laboratories shares now at ₹2,658. Accumulate on dips at ₹2,580. Keep the stop-loss at ₹2,480. Trail the stop-loss up to ₹2,695 as soon as the stock goes up to ₹2,730. — [Source](https://www.thehindubusinessline.com/portfolio/technical-analysis/stock-to-buy-today-caplin-point-laboratories-2658-buy/article71221000.ece) ## Business profile **Strategic vision:** Pharmaceutical company engaged in R&D, manufacturing, and marketing. ### Business segments - **Finished Formulations:** Production of a wide range of pharmaceutical formulations, covering over 36 therapeutic sections with more than 650 products. - **Active Pharmaceutical Ingredients (APIs):** Manufacturing of Active Pharmaceutical Ingredients (APIs) as part of its pharmaceutical product offerings. - **Clinical Research:** Engagement in clinical research activities related to pharmaceutical product development. ### Competitive strengths - Global product registrations across diverse geographies - USFDA/EU-GMP approved injectable facility - Extensive product portfolio covering numerous therapeutic sections ## Related stocks - [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30% - [Blue Jet Healthcare Limited (Healthcare)](https://faxioms.com/stocks/bluejet) — -3.23% - [Cohance Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/cohance) — -3.56% - [Concord Biotech Limited (Healthcare)](https://faxioms.com/stocks/concordbio) — -6.64% - [Eris Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/eris) — +0.58% ## Freshness and sources - Data as of: 2026-11-06 - Source: Faxioms public stock analysis API Canonical: https://faxioms.com/stocks/caplipoint Markdown representation: https://faxioms.com/stocks/caplipoint?render=md